Rosuvastatin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Familial Hypercholesterolemia
Conditions
Familial Hypercholesterolemia
Trial Timeline
Jul 1, 2006 → Jul 1, 2008
NCT ID
NCT00355615About Rosuvastatin + Placebo
Rosuvastatin + Placebo is a phase 3 stage product being developed by AstraZeneca for Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00355615. Target conditions include Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02546323 | Phase 3 | Completed |
| NCT00929734 | Phase 2 | Completed |
| NCT00951132 | Phase 2 | Withdrawn |
| NCT00990028 | Phase 1/2 | Completed |
| NCT00783042 | Phase 1 | Completed |
| NCT00673582 | Approved | Terminated |
| NCT00689416 | Phase 1 | Completed |
| NCT00329758 | Phase 2 | Completed |
| NCT00355615 | Phase 3 | Completed |
| NCT00658463 | Approved | Completed |
| NCT00800800 | Phase 3 | Completed |
Competing Products
20 competing products in Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Rosuvastatin 20mg + Placebo | AstraZeneca | Phase 3 | 77 |
| rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin 20mg | AstraZeneca | Phase 3 | 77 |
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Statins and Ezetimibe | Merck | Pre-clinical | 23 |
| Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo | Merck | Phase 3 | 77 |
| MK-0524A + MK-0524A | Merck | Phase 1 | 33 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| DFV890 | Novartis | Phase 2 | 52 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Inclisiran Sodium for injection + Placebo + Placebos | Novartis | Phase 3 | 77 |
| LCQ908 + Placebo | Novartis | Phase 3 | 77 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |